6326-06-3
6326-06-3 結(jié)構(gòu)式
基本信息
Benzenesulfonamide, 4-methyl-N-9H-xanthen-9-yl-
4-Methyl-N-(9H-xanthen-9-yl)-benzenesulfonamide
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/02/08 | HY-19996 | AH-7614 | 6326-06-3 | 1 mg | 280元 |
| 2025/02/08 | HY-19996 | AH 7614 AH-7614 | 6326-06-3 | 5mg | 700元 |
| 2025/02/08 | HY-19996 | AH-7614 | 6326-06-3 | 10 mM * 1 mLin DMSO | 770元 |
常見(jiàn)問(wèn)題列表
pIC50: 7.1 (human FFA4)
AH-7614 (compound 39) (0.063-1 μM) blocks intracellular Ca
2+
response induced by both linoleic acid and FFAR4 agonist in FFA4 expressing U2OS cells.
AH-7614 (100 μM) abolishes the enhancement in glucose-stimulated insulin secretion by GSK137647A in NCI-H716 cells.
AH-7614 (0.001-10 μM; 15 min) blocks TUG-891-mediated internalization of FFA4 from the cell surface (pIC
50
=7.70).
AH-7614 (10 μM; 30 min) blocks agonist-induced elevation of intracellular inositol monophosphates and phosphorylation of FFA4.
AH7614 (50?μg; intratumoral injection once every 4?d for 20 d) reduces the tumor growth in mice.
AH7614 (50?μg; intratumoral injection one day prior to epirubicin injection) enhances cancer cell sensitivity to the chemotherapy and inhibit tumor progression by blocking GPR120 signaling in combination with Epirubicin.